ATE541854T1 - Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung - Google Patents

Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung

Info

Publication number: ATE541854T1
Authority: AT; Austria
Prior art keywords: optionally substituted; production; aryl; composition containing; glucose
Prior art date: 2003-06-20

Application number

AT04746165T

Other languages

English (en)

Inventor

N Kikuchi

H Fujikura

S Tazawa

T Yamato

M Isaji

Original Assignee

Kissei Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-20

Filing date

2004-06-15

Publication date

2012-02-15

2004-06-15 Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE541854T1 publication Critical patent/ATE541854T1/de

Links

WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
101710195219 Sodium/glucose cotransporter Proteins 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
208000002249 Diabetes Complications Diseases 0.000 abstract 1
206010012655 Diabetic complications Diseases 0.000 abstract 1
229930091371 Fructose Natural products 0.000 abstract 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
239000005715 Fructose Substances 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
208000002705 Glucose Intolerance Diseases 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
235000014633 carbohydrates Nutrition 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
201000009104 prediabetes syndrome Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003217 pyrazoles Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/28—Two oxygen or sulfur atoms
- C07D231/30—Two oxygen or sulfur atoms attached in positions 3 and 5
- C07D231/32—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

AT04746165T 2003-06-20 2004-06-15 Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung ATE541854T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2003175663		2003-06-20
PCT/JP2004/008695 WO2004113359A1 (ja)	2003-06-20	2004-06-15	ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体

Publications (1)

Publication Number	Publication Date
ATE541854T1 true ATE541854T1 (de)	2012-02-15

Family

ID=33534874

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04746165T ATE541854T1 (de)	2003-06-20	2004-06-15	Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung

Country Status (7)

Country	Link
US (1)	US7576064B2 (de)
EP (1)	EP1637539B1 (de)
JP (1)	JP4708187B2 (de)
AT (1)	ATE541854T1 (de)
CA (1)	CA2529878C (de)
ES (1)	ES2377741T3 (de)
WO (1)	WO2004113359A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2004137245A (ja) *	2002-08-23	2004-05-13	Kissei Pharmaceut Co Ltd	ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CN104109155A (zh)	2003-08-01	2014-10-22	田边三菱制药株式会社	新颖化合物
US8785403B2 (en)	2003-08-01	2014-07-22	Mitsubishi Tanabe Pharma Corporation	Glucopyranoside compound
US7375090B2 (en)	2003-08-26	2008-05-20	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
AU2005219776B2 (en)	2004-03-04	2010-07-08	Kissei Pharmaceutical Co., Ltd.	Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
US7838552B2 (en)	2004-06-04	2010-11-23	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
US7803838B2 (en)	2004-06-04	2010-09-28	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
DE102004028241B4 (de) *	2004-06-11	2007-09-13	Sanofi-Aventis Deutschland Gmbh	Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
TW200637869A (en)	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP4888840B2 (ja) *	2005-07-22	2012-02-29	味の素株式会社	ピラゾール−ｏ−グリコシド誘導体の調製方法及び前記方法の新規中間体
UY30082A1 (es)	2006-01-11	2007-08-31	Boehringer Ingelheim Int	Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
UY30730A1 (es)	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
MX2010002695A (es) *	2007-09-10	2010-04-01	Janssen Pharmaceutica Nv	Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2010018438A2 (en) *	2008-08-11	2010-02-18	Hetero Research Foundation	Tetrazole glycosides
ES2380408T3 (es) *	2008-08-28	2012-05-11	Pfizer Inc.	Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
CN101445528B (zh) *	2008-12-25	2011-06-15	天津药物研究院	硫代葡萄糖衍生物、其制备方法和用途
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
JP5658751B2 (ja)	2009-07-10	2015-01-28	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	１−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンのための結晶化方法
WO2011047113A1 (en) *	2009-10-14	2011-04-21	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
US8669380B2 (en)	2009-11-02	2014-03-11	Pfizer Inc.	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
NZ703128A (en)	2010-05-11	2016-04-29	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
WO2012140120A1 (en)	2011-04-13	2012-10-18	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
TWI542596B (zh)	2011-05-09	2016-07-21	健生藥品公司	（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
EP2937096B1 (de) *	2014-04-23	2019-08-21	Julius-Maximilians-Universität Würzburg	Aus RS1 abgeleitete Peptide, die Glukoseabsorption nach einer glukosereichen Mahlzeit herunterregulieren und die Insulinsensitivität steigern
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN108456182A (zh) *	2018-01-25	2018-08-28	于磊	Sglt2蛋白的抑制剂以及应用
TWI805727B (zh) *	2018-04-04	2023-06-21	日商日本煙草產業股份有限公司	經雜芳基取代之吡唑化合物及其醫藥用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2529891A1 (fr) *	1982-07-12	1984-01-13	Nativelle Sa Ets	Derives du pyridyl-3 alcoxy-5 pyrazole, procede de preparation et application en therapeutique
FR2529786A1 (fr) *	1982-07-12	1984-01-13	Nativelle Sa Ets	Compositions pharmaceutiques a base de derives de la pyrazolone-5, nouveaux produits et procede de preparation
EP1213296B1 (de) *	1999-08-31	2004-04-14	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
US6555519B2 (en) *	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
WO2002036602A1 (en) *	2000-11-02	2002-05-10	Ajinomoto Co., Inc.	Novel pyrazole derivatives and diabetes remedies containing the same
SK287786B6 (sk) *	2000-12-28	2011-09-05	Kissei Pharmaceutical Co., Ltd.	Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
EP1364957B1 (de) *	2001-02-26	2008-12-31	Kissei Pharmaceutical Co., Ltd.	Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
WO2002068440A1 (en) *	2001-02-27	2002-09-06	Kissei Pharmaceutical Co., Ltd.	Glycopyranosyloxypyrazole derivatives and medicinal use thereof
EP1389621A4 (de) *	2001-04-27	2005-05-11	Ajinomoto Kk	N-substituierte pyrazolyl-o-glykosidderivate und diese enthaltendes diabetesmittel
CA2448741C (en) *	2001-05-30	2010-06-22	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JP4115105B2 (ja) *	2001-07-02	2008-07-09	協和醗酵工業株式会社	ピラゾール誘導体
JP4284091B2 (ja) *	2002-03-27	2009-06-24	キッセイ薬品工業株式会社	単糖類共輸送担体
EP1568380A4 (de) *	2002-12-04	2009-10-21	Kissei Pharmaceutical	Vorbeugende massnahme oder heilmittel für krankheiten aufgrund von blutzuckererhöhung

2004
- 2004-06-15 WO PCT/JP2004/008695 patent/WO2004113359A1/ja not_active Ceased
- 2004-06-15 AT AT04746165T patent/ATE541854T1/de active
- 2004-06-15 US US10/561,217 patent/US7576064B2/en not_active Expired - Fee Related
- 2004-06-15 ES ES04746165T patent/ES2377741T3/es not_active Expired - Lifetime
- 2004-06-15 JP JP2005507253A patent/JP4708187B2/ja not_active Expired - Fee Related
- 2004-06-15 EP EP04746165A patent/EP1637539B1/de not_active Expired - Lifetime
- 2004-06-15 CA CA2529878A patent/CA2529878C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1637539B1 (de)	2012-01-18
WO2004113359A1 (ja)	2004-12-29
EP1637539A4 (de)	2009-06-17
ES2377741T3 (es)	2012-03-30
US7576064B2 (en)	2009-08-18
CA2529878A1 (en)	2004-12-29
JP4708187B2 (ja)	2011-06-22
CA2529878C (en)	2012-11-20
JPWO2004113359A1 (ja)	2006-07-27
US20070060531A1 (en)	2007-03-15
EP1637539A1 (de)	2006-03-22

Publication	Publication Date	Title
EP1637539A4 (de)	2009-06-17	Pyrazolderivat, arzneimittelzusammensetzung, die dieses enthält, und zwischenprodukt für dessen herstellung
DE60332743D1 (de)	2010-07-08	Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
EP1609798A4 (de)	2009-06-17	Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung
CA2474578A1 (en)	2003-08-21	Novel pyridin- and pyrimidin-derivatives
EP1400529A4 (de)	2007-12-19	Glucopyranosyloxypyrazol derivat, diese enthaltende medizinische zusammensetzung, dessen medizinische verwendung und zwischenprodukt zu dessen herstellung
UY27666A1 (es)	2003-08-29	Nuevos derivados de piridina y quinolina
ATE264337T1 (de)	2004-04-15	Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
ATE312114T1 (de)	2005-12-15	Glucopyranosyloxy-benzylbenzen-derivate, medizinische zusammensetzung und zwischenprodukte für die herstellung der derivate
NO20055680L (no)	2006-01-11	Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20064412L (no)	2006-12-04	Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav
WO2005021566A3 (de)	2005-04-07	Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
NO20072389L (no)	2007-08-23	Substituerte benzokinolizinderivater
WO2003011880A1 (fr)	2003-02-13	Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
MY129023A (en)	2007-03-30	Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
DE50309979D1 (de)	2008-07-24	Neue purinderivate, deren herstelllung und deren verwendung als arzneimittel
TW200637839A (en)	2006-11-01	1-thio-d-glucitol derivatives
TW200505919A (en)	2005-02-16	DPP-IV inhibitors
WO2005037798A3 (en)	2005-06-16	Amide or thiomide derivatives and their use in the treatment of pain
ATE430743T1 (de)	2009-05-15	Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
DK1483246T3 (da)	2006-04-10	5-Substituerede alkylaminopyrazolderivater som pesticider
EP1634874A4 (de)	2008-04-02	Imidazolidinderivate
EP1550668A4 (de)	2008-10-01	Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, dessen medizinische verwendung und zwischenprodukt für dessen herstellung
ATE420853T1 (de)	2009-01-15	5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung
NO20063859L (no)	2006-08-29	Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter
NO20073710L (no)	2007-08-31	Kjemiske forbindelser